The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life
- 1 June 2020
- Vol. 75 (6), 1460-1463
- https://doi.org/10.1111/all.14135
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- One year of mepolizumab. Efficacy and safety in real-life in ItalyPulmonary Pharmacology & Therapeutics, 2019
- Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real‐life observationAllergy, 2019
- Eosinophils Target Therapy for Severe Asthma: Critical PointsBioMed Research International, 2018
- Biological therapies for eosinophilic asthmaExpert Opinion on Biological Therapy, 2018
- The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trialsWorld Allergy Organization Journal, 2018
- Is it severe asthma or asthma with severe comorbidities?Journal of Asthma and Allergy, 2017
- Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trialThe Lancet Respiratory Medicine, 2017
- Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studiesThe Lancet Respiratory Medicine, 2016
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaThe New England Journal of Medicine, 2014